AZTA Quote, Financials, Valuation and Earnings

Bionano Genomics, Inc. has a net margin of -3.49% compared to Azenta, Inc.'s net margin of -115.42%. Azenta, Inc.'s return on equity of 1.7% beat Bionano Genomics, Inc.'s return on equity of -84.77%.

Azenta, Inc. has a consensus price target of $38.67, signalling upside risk potential of 43.32%. On the other hand Bionano Genomics, Inc. has an analysts' consensus of $7.50 which suggests that it could grow by 552.17%. Given that Bionano Genomics, Inc. has higher upside potential than Azenta, Inc., analysts believe Bionano Genomics, Inc. is more attractive than Azenta, Inc..

Azenta, Inc. has a beta of 1.349, which suggesting that the stock is 34.927% more volatile than S&P 500. In comparison Bionano Genomics, Inc. has a beta of 1.683, suggesting its more volatile than the S&P 500 by 68.319%.

Azenta, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bionano Genomics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Azenta, Inc. pays -- of its earnings as a dividend. Bionano Genomics, Inc. pays out -- of its earnings as a dividend.

Azenta, Inc. quarterly revenues are $148.6M, which are larger than Bionano Genomics, Inc. quarterly revenues of $7.4M. Azenta, Inc.'s net income of -$5.2M is higher than Bionano Genomics, Inc.'s net income of -$8.5M. Notably, Azenta, Inc.'s price-to-earnings ratio is -- while Bionano Genomics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Azenta, Inc. is 2.08x versus 0.13x for Bionano Genomics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Bruker Corp. has a net margin of -3.49% compared to Azenta, Inc.'s net margin of 2.99%. Azenta, Inc.'s return on equity of 1.7% beat Bruker Corp.'s return on equity of -0.39%.

Azenta, Inc. has a consensus price target of $38.67, signalling upside risk potential of 43.32%. On the other hand Bruker Corp. has an analysts' consensus of $48.43 which suggests that it could grow by 20.74%. Given that Azenta, Inc. has higher upside potential than Bruker Corp., analysts believe Azenta, Inc. is more attractive than Bruker Corp..

Azenta, Inc. has a beta of 1.349, which suggesting that the stock is 34.927% more volatile than S&P 500. In comparison Bruker Corp. has a beta of 1.186, suggesting its more volatile than the S&P 500 by 18.621%.

Azenta, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker Corp. offers a yield of 0.5% to investors and pays a quarterly dividend of $0.05 per share. Azenta, Inc. pays -- of its earnings as a dividend. Bruker Corp. pays out 26.44% of its earnings as a dividend. Bruker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Azenta, Inc. quarterly revenues are $148.6M, which are smaller than Bruker Corp. quarterly revenues of $977.2M. Azenta, Inc.'s net income of -$5.2M is lower than Bruker Corp.'s net income of $29.2M. Notably, Azenta, Inc.'s price-to-earnings ratio is -- while Bruker Corp.'s PE ratio is 77.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Azenta, Inc. is 2.08x versus 1.77x for Bruker Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Harvard Bioscience, Inc. has a net margin of -3.49% compared to Azenta, Inc.'s net margin of -5.98%. Azenta, Inc.'s return on equity of 1.7% beat Harvard Bioscience, Inc.'s return on equity of -155.33%.

Azenta, Inc. has a consensus price target of $38.67, signalling upside risk potential of 43.32%. On the other hand Harvard Bioscience, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 225.89%. Given that Harvard Bioscience, Inc. has higher upside potential than Azenta, Inc., analysts believe Harvard Bioscience, Inc. is more attractive than Azenta, Inc..

Azenta, Inc. has a beta of 1.349, which suggesting that the stock is 34.927% more volatile than S&P 500. In comparison Harvard Bioscience, Inc. has a beta of 1.548, suggesting its more volatile than the S&P 500 by 54.788%.

Azenta, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Harvard Bioscience, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Azenta, Inc. pays -- of its earnings as a dividend. Harvard Bioscience, Inc. pays out -- of its earnings as a dividend.

Azenta, Inc. quarterly revenues are $148.6M, which are larger than Harvard Bioscience, Inc. quarterly revenues of $20.6M. Azenta, Inc.'s net income of -$5.2M is lower than Harvard Bioscience, Inc.'s net income of -$1.2M. Notably, Azenta, Inc.'s price-to-earnings ratio is -- while Harvard Bioscience, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Azenta, Inc. is 2.08x versus 0.31x for Harvard Bioscience, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Revvity, Inc. has a net margin of -3.49% compared to Azenta, Inc.'s net margin of 12.41%. Azenta, Inc.'s return on equity of 1.7% beat Revvity, Inc.'s return on equity of 3.2%.

Azenta, Inc. has a consensus price target of $38.67, signalling upside risk potential of 43.32%. On the other hand Revvity, Inc. has an analysts' consensus of $119.56 which suggests that it could grow by 21.62%. Given that Azenta, Inc. has higher upside potential than Revvity, Inc., analysts believe Azenta, Inc. is more attractive than Revvity, Inc..

Azenta, Inc. has a beta of 1.349, which suggesting that the stock is 34.927% more volatile than S&P 500. In comparison Revvity, Inc. has a beta of 1.066, suggesting its more volatile than the S&P 500 by 6.609%.

Azenta, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Revvity, Inc. offers a yield of 0.29% to investors and pays a quarterly dividend of $0.07 per share. Azenta, Inc. pays -- of its earnings as a dividend. Revvity, Inc. pays out 13.49% of its earnings as a dividend. Revvity, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Azenta, Inc. quarterly revenues are $148.6M, which are smaller than Revvity, Inc. quarterly revenues of $772.1M. Azenta, Inc.'s net income of -$5.2M is lower than Revvity, Inc.'s net income of $95.8M. Notably, Azenta, Inc.'s price-to-earnings ratio is -- while Revvity, Inc.'s PE ratio is 47.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Azenta, Inc. is 2.08x versus 4.01x for Revvity, Inc.. Usually stocks with elevated PS ratios are considered overvalued.